Shaily Engineering Plastics Ltd (SHAILY) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management is confident it will exceed its FY27 guidance of 36 million pen devices, citing strong demand and new capacity coming online.
- The newly launched 'Toby' reusable auto-injector is a key strategic product designed to attract innovator pharma partners by addressing sustainability and cost concerns.
- The company is actively seeking innovator pharma partners and is confident of securing one or two by the end of calendar year 2027.
Performance Overview
- The company achieved its highest-ever quarterly revenue, driven by robust performance in the healthcare segment.
- Healthcare has become the primary business driver, now constituting 55% of total revenue, with a significant 78% year-on-year growth.
- Gross margins recovered to 60%, showing resilience against input cost volatility and geopolitical uncertainties.
- The consumer business has stabilized over two consecutive quarters, although it continues to operate below the previous year's levels.
- The company's credit rating for short-term facilities was upgraded by CARE Ratings to CARE A1+, reflecting a strengthening financial position and improving leverage.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.